Citations

Clear

439 citation(s) found for "Stone, M".

Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device
Kar, Saibal , Doshi, Shephal K. , Sadhu, Ashish, Horton, Rodney , Osorio, José , Stone, James, Shah, Manish H. , Dukkipati, Srinivas R. , Adler, Stuart W., Kim, Jamie , Wazni, Oussama M. , Price, Mathew J., Holmes, David R. , Shipley, Robert D., Gordon, Nicole, Allocco, Dominic J. , Investigators, On behalf of the PINNACLE FLX, Kar, Saibal , Ellis, Christopher R. , Nair, Devi G , Asch, Federico M. , Reddy, Vivek Y. , Investigators, On behalf of the PINNACLE FLX

Mayo Clinic

Circulation | April 6, 2021 | Volume: 143 | Issue: 18 | Pages: 1754-1762

10.1161/circulationaha.120.050117 | PMID 33820423 Get It

Background: Left atrial appendage (LAA) occlusion provides an alternative to oral anticoagulation for thromboembolic risk reduction in patients with nonvalvular atrial fibrillation. Since regulatory approval in 2015, the WATCHMAN device has been the only LAA closure device available for clinical use in the United States. The PINNACLE FLX study (Protection Against Embolism for Nonvalvular AF Patients: Investigational Device Evaluation of the Watchman FLX LAA Closure Technology) evaluated the safety and effectiveness of the next-generation WATCHMAN FLX LAA closure device in patients with nonvalvular atrial fibrillation in whom oral anticoagulation is indicated, but who have an appropriate rationale to seek a nonpharmaceutical alternative. Methods: This was a prospective, nonrandomized, multicenter US Food and Drug Administration study. The primary safety end point was the occurrence of one of the following events within 7 days after the procedure or by hospital discharge, whichever was later: death, ischemic stroke, systemic embolism, or device- or procedure-related events requiring cardiac surgery. The primary effectiveness end point was the incidence of effective LAA closure (peri-device flow ≤5 mm), as assessed by the echocardiography core laboratory at 12-month follow-up. Results: A total of 400 patients were enrolled. The mean age was 73.8±8.6 years and the mean CHA 2 DS 2 -VASc score was 4.2±1.5. The incidence of the primary safety end point was 0.5% with a 1-sided 95% upper CI of 1.6%, meeting the performance goal of 4.2% ( P <0.0001). The incidence of the primary effectiveness end point was 100%, with a 1-sided 95% lower CI of 99.1%, again meeting the performance goal of 97.0% ( P <0.0001). Device-related thrombus was reported in 7 patients, no patients experienced pericardial effusion requiring open cardiac surgery, and there were no device embolizations. Conclusions: LAA closure with this next-generation LAA closure device was associated with a low incidence of adverse events and a high incidence of anatomic closure. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02702271.
Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial
Gertz, Zachary M. , Herrmann, Howard C. , Lim, D. Scott , Kapadia, Samir , Reed, Grant W. , Puri, Rishi , Krishnaswamy, Amar , Gersh, Bernard J. , Weissman, Neil J., Grayburn, Paul , Redfors, Björn , Zhang, Zixuan , Abraham, William T. , Stone, Gregg W. , Mack, Michael J. , Kapadia, Samir , Herrmann, Howard C , Gersh, Bernard J , Reed, Grant W , Lim, D Scott , Kar, Saibal , Asch, Federico M. , Kosmidou, Ioanna , Lindenfeld, JoAnn

Mayo Clinic

Circulation: Cardiovascular Interventions | March 15, 2021 | Volume: 14 | Issue: 4 | Pages: No page available

10.1161/circinterventions.120.010300 | PMID 33719505 Get It

Background: Atrial fibrillation (AF), mitral regurgitation (MR), and left ventricular (LV) ejection fraction have a complex interplay. We evaluated the role of AF in patients with heart failure and moderate-to-severe or severe secondary MR enrolled in the randomized COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) and its impact on mechanisms and outcomes with the MitraClip. Methods: Patients in the COAPT trial were stratified by the presence (n=327) or absence (n=287) of a history of AF and by assignment to treatment group. Clinical, echocardiographic, and outcome measures were assessed. The primary outcome was the composite rate of death or heart failure hospitalization at 24 months. Results: Patients with history of AF were older and more often male. They had a higher LV ejection fraction, larger left atrial volumes and mitral valve orifice areas, smaller LV volumes, and similar MR severity. Patients with AF compared with those without a history of AF had a higher unadjusted (hazard ratio [HR], 1.32 [95% CI, 1.06–1.64], P =0.01) and adjusted (HR, 1.30 [1.03–1.64], P =0.03) 2-year rate of the primary outcome. Treatment with the MitraClip compared with guideline-directed medical therapy alone reduced death or heart failure hospitalization in both those with (HR, 0.61 [0.46–0.82]) and without (HR, 0.46 [0.33–0.66]) a history of AF ( P int =0.18). Treatment with the MitraClip was associated with a lower risk of stroke in patients with a history of AF (HR, 0.18 [0.04–0.86]) but not in those without a history of AF (HR, 1.64 [0.58–4.62]; P int =0.02). Conclusions: In the COAPT trial, patients with a history of AF had larger left atrial and mitral valve orifice areas with higher LV ejection fraction and smaller LV volumes, suggesting an atrial mechanism contribution to functional MR. Despite the worse prognosis of heart failure patients with a history of AF, MR reduction with the MitraClip still afforded substantial clinical benefits. Treatment with MitraClip was associated with a lower risk of stroke in patients with a history of AF. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01626079.
Dural augmentation approaches and complication rates after posterior fossa decompression for Chiari I malformation and syringomyelia: a Park-Reeves Syringomyelia Research Consortium study
Adelson, P. David , Akbari, S. Hassan A. , Albert, Gregory W. , Aldana, Philipp R. , Alden, Tord D. , Anderson, Richard C. E. , Bauer, David F. , Bethel-Anderson, Tammy, Brockmeyer, Douglas L. , Chern, Joshua J. , Couture, Daniel E., Durham, Susan, Ellenbogen, Richard G. , Eskandari, Ramin , George, Timothy M., Greene, Stephanie , Gross, Naina L. , Guillaume, Daniel, Hankinson, Todd C. , Heuer, Gregory G. , Iantosca, Mark, Iskandar, Bermans J. , Jackson, Eric M. , Keating, Robert F., Krieger, Mark D., Leonard, Jeffrey R. , Maher, Cormac O. , Mangano, Francesco T. , McComb, J. Gordon , McEvoy, Sean D., Meehan, Thanda, O’Neill, Brent R., Olavarria, Greg, Ragheb, John , Shannon, Chevis N. , Smyth, Matthew D. , Stone, Scellig , Strahle, Jennifer M. , Torner, James C., Tuite, Gerald F. , Wait, Scott D. , Wellons, John C. , Whitehead, William E. , Park, Tae Sung, Limbrick, David D. , Torner, James C. , Yahanda, Alexander T. , Daniels, David J. , Dlouhy, Brian J , Grant, Gerald A. , Graupman, Patrick C. , Greenfield, Jeffrey P. , Guillaume, Daniel J., Johnston, James M. , Menezes, Arnold H. , Selden, Nathan R. W. , Shah, Manish N. , Shimony, Joshua S. , Limbrick, David D.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | February 12, 2021 | Volume: 27 | Issue: 4 | Pages: 459-468

10.3171/2020.8.peds2087 | PMID 33578390 Get It

OBJECTIVE Posterior fossa decompression with duraplasty (PFDD) is commonly performed for Chiari I malformation (CM-I) with syringomyelia (SM). However, complication rates associated with various dural graft types are not well established. The objective of this study was to elucidate complication rates within 6 months of surgery among autograft and commonly used nonautologous grafts for pediatric patients who underwent PFDD for CM-I/SM. METHODS The Park-Reeves Syringomyelia Research Consortium database was queried for pediatric patients who had undergone PFDD for CM-I with SM. All patients had tonsillar ectopia ≥ 5 mm, syrinx diameter ≥ 3 mm, and ≥ 6 months of postoperative follow-up after PFDD. Complications (e.g., pseudomeningocele, CSF leak, meningitis, and hydrocephalus) and postoperative changes in syrinx size, headaches, and neck pain were compared for autograft versus nonautologous graft. RESULTS A total of 781 PFDD cases were analyzed (359 autograft, 422 nonautologous graft). Nonautologous grafts included bovine pericardium (n = 63), bovine collagen (n = 225), synthetic (n = 99), and human cadaveric allograft (n = 35). Autograft (103/359, 28.7%) had a similar overall complication rate compared to nonautologous graft (143/422, 33.9%) (p = 0.12). However, nonautologous graft was associated with significantly higher rates of pseudomeningocele (p = 0.04) and meningitis (p < 0.001). The higher rate of meningitis was influenced particularly by the higher rate of chemical meningitis (p = 0.002) versus infectious meningitis (p = 0.132). Among 4 types of nonautologous grafts, there were differences in complication rates (p = 0.02), including chemical meningitis (p = 0.01) and postoperative nausea/vomiting (p = 0.03). Allograft demonstrated the lowest complication rates overall (14.3%) and yielded significantly fewer complications compared to bovine collagen (p = 0.02) and synthetic (p = 0.003) grafts. Synthetic graft yielded higher complication rates than autograft (p = 0.01). Autograft and nonautologous graft resulted in equal improvements in syrinx size (p < 0.0001). No differences were found for postoperative changes in headaches or neck pain. CONCLUSIONS In the largest multicenter cohort to date, complication rates for dural autograft and nonautologous graft are similar after PFDD for CM-I/SM, although nonautologous graft results in higher rates of pseudomeningocele and meningitis. Rates of meningitis differ among nonautologous graft types. Autograft and nonautologous graft are equivalent for reducing syrinx size, headaches, and neck pain.
WoCoVA consensus on the clinical use of in-line filtration during intravenous infusions: Current evidence and recommendations for future research
Boxtel, Ton van , Pittiruti, Mauro , Arkema, A., Ball, Patrick , Bertoglio, Sergio , Biffi, Roberto , Dupont, Christian , Fonzo‐Christe, Caroline, Foster, Jann , Keck, Cornelia M. , Ray‐Barruel, Gillian , Sasse, Michael , Hadaway, Lynn, Ryder, Marcia, Schears, Gregory, Stone, Josie, Van Boxtel, Ton , Bertoglio, Sergio , Biffi, Roberto , Barone, Giovanni , Jones, Matthew, Scoppettuolo, Giancarlo , Hoogen, Agnes van den , Villa, Gianluca

Mayo Clinic

The Journal of Vascular Access | January 28, 2021 | Volume: 23 | Issue: 2 | Pages: 179-191

10.1177/1129729821989165 | PMID 33506747 Get It

The need for filtering intravenous infusions has long been recognized in the field of venous access, though hard scientific evidence about the actual indications for in-line filters has been scarce. In the last few years, several papers and a few clinical studies have raised again this issue, suggesting that the time has come for a proper definition of the type of filtration, of its potential benefit, and of its proper indications in clinical practice. The WoCoVA Foundation, whose goal is to increase the global awareness on the risk of intravenous access and on patients’ safety, developed the project of a consensus on intravenous filtration. A panel of experts in different aspects of intravenous infusion was chosen to express the current state of knowledge about filtration and to indicate the direction of future research in this field. The present document reports the final conclusions of the panel.
To stent or not to stent? Treating angina after ISCHEMIA—introduction
Gersh, Bernard J. , Boden, William E. , Bhatt, Deepak L. , Stone, Peter H. , Crea, Filippo , Crea, Filippo , Lüscher, Thomas F , Bhatt, Deepak L , Gersh, Bernard J , Crea, Filippo

Mayo Clinic

European Heart Journal | January 25, 2021 | Volume: 42 | Issue: 14 | Pages: 1387-1400

10.1093/eurheartj/ehab069 | PMID 33827136 Get It

Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia
Advani, Anjali S. , Larsen, Eric , Laumann, Kristina, Luger, Selina M. , Liedtke, Michaela , Devidas, Meenakshi , Chen, Zhiguo , Yin, Jun , Claxton, David F. , Coffan, Kristin, Tallman, Martin S. , Appelbaum, Frederick R. , Stone, Richard M. , McNeer, Jennifer L. , Loh, Mignon L. , Raetz, Elizabeth A. , Carroll, William L. , Claxton, David F , Loh, Mignon L , Advani, Anjali S , Devidas, Meenakshi , Foster, Matthew C , Erba, Harry Paul , Hunger, Stephen P. , Winick, Naomi Joan , Larson, Richard A. , Stock, Wendy

Mayo Clinic

Blood Advances | January 23, 2021 | Volume: 5 | Issue: 2 | Pages: 504-512

10.1182/bloodadvances.2020002439 | PMID 33496745 Get It

Abstract Adolescents and young adults (AYAs) with acute lymphoblastic leukemia have improved outcomes when treated with pediatric-inspired regimens. CALGB 10403 was the largest prospective study to evaluate the feasibility of using a pediatric regimen in AYAs with acute lymphoblastic leukemia up to 40 years of age. This article presents the toxicity events observed in the CALGB 10403 study and compares these toxicities vs those observed among AYAs treated on the same arm of the companion Children’s Oncology Group (COG) AALL0232 study. Toxicities in CALGB 10403 were similar to those observed in COG AALL0232. Some grade 3 to 4 adverse events were more often reported in CALGB 10403 compared with COG AALL0232 (hyperglycemia, hyperbilirubinemia, transaminase elevation, and febrile neutropenia). Adverse events correlated with body mass index ≥30 kg/m2 and some with increasing age. The mortality rate in CALGB 10403 was low (4%) and similar to that in the COG AALL0232 trial. A caveat to this analysis is that only 39% of CALGB 10403 patients completed all planned protocol treatment. In COG AALL0232, although 74% of patients aged &lt;18 years completed treatment, only 57% of patients aged ≥18 years completed treatment. This scenario suggests that issues associated with age and treating physician may be a factor. Due to its improved survival rates compared with historical controls, the CALGB 10403 regimen is now a standard of care. The hope is that the rate of protocol completion will increase as more familiarity is gained with this regimen. These trials were registered at www.clinicaltrials.gov as #NCT00558519 (CALGB 10403) and #NCT00075725 (COG AALL0232).
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021
Altman, Jessica K. , Assi, Rita, Bachiashvili, Kimo, Fathi, Amir T. , Fedorov, Kateryna, Foran, James M. , Gojo, Ivana , Goldberg, Aaron, Hall, Aric C. , Jonas, Brian A., Levine, Matthew R., Mangan, James, Mannis, Gabriel N. , Marcucci, Guido , Moriarty, Kelsey, Ali, Moaath Mustafa, Neff, Jadee , Nejati, Reza , Olin, Rebecca L. , Patel, Anand, Percival, Mary‐Elizabeth M. , Perl, Alexander E. , Pettit, Kristen, Rao, Dinesh S. , Ravandi‐Kashani, Farhad, Schwabkey, Zaker, Shallis, Rory, Stahl, Maximilian, Stone, Richard M. , Thota, Swapna, Uy, Geoffrey L., Walker, Alison, Wang, Eunice, Awotiwon, Ajibola, Roth, Sydney L., Stehman, Katie, Strickland, Stephen A. , Przespolewski, Amanda , Strickland, Stephen Anthony , Pollyea, Daniel Aaron , Assi, Rita, Bachiashvili, Kimo, Bhatt, Vijaya Raj , Fedorov, Kateryna, Goldberg, Aaron, Jonas, Brian A., Levine, Matthew R., Mangan, James, Mims, Alice S , Moriarty, Kelsey, Ali, Moaath Mustafa, Patel, Anand, Pettit, Kristen, Schwabkey, Zaker, Shallis, Rory, Stahl, Maximilian, Thota, Swapna, Uy, Geoffrey L., Walker, Alison, Wang, Eunice, Awotiwon, Ajibola, Roth, Sydney L., Stehman, Katie

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 6, 2021 | Volume: 19 | Issue: 1 | Pages: 16-27

10.6004/jnccn.2021.0002 | PMID 33406488 Get It

The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.
Subperiosteal Orbital Hematoma: An Uncommon Complication of Acute Sinusitis
Whitlock, Joseph P., Bhatt, Alok A. , Stone, Jeffrey A, Bhatt, Alok A , Stone, Jeffrey A.

Mayo Clinic

Journal of Clinical Imaging Science | December 20, 2020 | Volume: 10 | Issue: No issue available | Pages: 85

10.25259/jcis_209_2020 | PMID 33408960 Get It

Non-traumatic subperiosteal orbital hematoma is a rare finding and uncommon cause of proptosis. Reported cases describe an association with increased venous pressure. However, it is important to note that there is also an association with sinusitis, which must be differentiated from subperiosteal abscess. This article describes the unique imaging features of subperiosteal hematoma in the setting of sinusitis, as well as the suspected pathophysiology.
Three Medicolegal Cases of Searching for the Stone: Lessons Learned Along the Journey
Jacobson, Ashley , Moore, Gregory P. , Boie, Eric T., Sakamoto, Ayumi , Jacobson, Ashley A, Sakamoto, Ayumi E, Moore, Gregory

Mayo Clinic

Clinical Practice and Cases in Emergency Medicine | November 17, 2020 | Volume: 4 | Issue: 4 | Pages: 505-508

10.5811/cpcem.2020.9.48652 | PMID 33217257 Get It

We present three medicolegal cases of medical negligence settled out of court. These cases all involved patients who presented to the emergency department (ED) with a suspected diagnosis of kidney stone. Highlighted are the importance of patient communication, addressing incidental findings found during a patient’s ED visit, anticipating complications, and the need for thorough documentation.
Retained Foreign Body Presenting as Pouch Stone After Continent Urinary Diversion
Patel, Maya, Nevo, Amihay , Stern, Karen , Stern, Karen L, Stern, Karen L

Mayo Clinic

Journal of Endourology Case Reports | November 16, 2020 | Volume: 6 | Issue: 4 | Pages: 465-467

10.1089/cren.2020.0100 | PMID 33457703 Get It

Background: Continent urinary diversion is a procedure commonly performed in patients after cystectomy who wish to not have a urostomy. Well-documented complications after continent urinary diversion include urinary tract infections and formation of urinary stones. However, these are typically late complications, and few reports have described the onset of these urinary symptoms within 12 months of initial continent urinary diversion. Case Presentation: Herein we report a case of a 41-year-old woman with history of cystectomy with continent urinary diversion who presents with recurrent infections and a calculus in the pouch 10 months after the initial procedure. Upon surgical exploration for removal of the stone, it was discovered that the stone was in fact a calcified retained catheter tip. Conclusion: This case further highlights that stone formation within 12 months of a urinary diversion is unusual and should prompt additional work-up for foreign body.